Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits

Journal of Virology

Volumn 83, Issue 11, 2009, Pages 5933-5938

  Liu, Jia ^a   Wennier, Sonia ^a   Reinhard, Mary ^b   Roy, Edward ^c   MacNeill, Amy ^d   McFadden, Grant ^a,e  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; RED FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; KINETICS; MYXOMA VIRUS; MYXOMATOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; GENE VECTOR; GENETICS; METABOLISM; PATHOGENICITY; PATHOLOGY; PLASMID; RABBIT; SURVIVAL RATE; VIRUS REPLICATION;

ANIMALIA; MYXOMA VIRUS; ORYCTOLAGUS CUNICULUS; POXVIRIDAE;

ANIMALS; GENETIC VECTORS; INTERLEUKIN-15; KINETICS; MYXOMA VIRUS; MYXOMATOSIS, INFECTIOUS; PLASMIDS; RABBITS; SURVIVAL RATE; VIRUS REPLICATION;

EID: 66149114469     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00204-09     Document Type: Article

References (38)

1. Adams, M. M., A. D. Rice, and R. W. Moyer. 2007. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J. Virol. 81:11084-11095. (Pubitemid 47536081)
2. Barrett, J. W., L. R. Alston, F. Wang, M. M. Stanford, P. A. Gilbert, X. Gao, J. Jimenez, D. Villeneuve, P. Forsyth, and G. McFadden. 2007. Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J. Neurovirol. 13:549-560.
3. Basak, G. W., L. Zapala, P. J. Wysocki, A. Mackiewicz, M. Jakobisiak, and W. Lasek. 2008. Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model. Oncol Rep. 19:1173-1179.
4. Best, S. M., S. V. Collins, and P. J. Kerr. 2000. Coevolution of host and virus: cellular localization of virus in myxoma virus infection of resistant and susceptible European rabbits. Virology 277:76-91.
5. Calarota, S. A., A. Dai, J. N. Trocio, D. B. Weiner, F. Lori, and J. Lisziewicz. 2008. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine 26:5188-5195.
6. Cameron, C., S. Hota-Mitchell, L. Chen, J. Barrett, J. X. Cao, C. Macaulay, D. Willer, D. Evans, and G. McFadden. 1999. The complete DNA sequence of myxoma virus. Virology 264:298-318.
7. Evans, R., J. A. Fuller, G. Christianson, D. M. Krupke, and A. B. Troutt. 1997. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell Immunol. 179:66-73. (Pubitemid 27360105)
8. Fehniger, T. A., M. A. Cooper, and M. A. Caligiuri. 2002. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. 13:169-183. (Pubitemid 34229391)
9. Imamichi, H., I. Sereti, and H. C. Lane. 2008. IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3. Eur. J. Immunol. 38:1621-1630.
10. Johnston, J. B., and G. McFadden. 2004. Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol. 6:695-705. (Pubitemid 39077377)
11. Kerr, P., and G. McFadden. 2002. Immune responses to myxoma virus. Viral Immunol. 15:229-246. (Pubitemid 34651528)
12. Kobayashi, H., S. Dubois, N. Sato, H. Sabzevari, Y. Sakai, T. A. Waldmann, and Y. Tagaya. 2005. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105:721-727.
13. Kovanen, P. E., and W. J. Leonard. 2004. Cytokines and immunodeficiency diseases: critical roles of the gamma (c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 202:67-83.
14. + memory T cells by opposing cytokines. Science 288:675-678.
15. Lun, X., W. Yang, T. Alain, Z. Q. Shi, H. Muzik, J. W. Barrett, G. McFadden, J. Bell, M. G. Hamilton, D. L. Senger, and P. A. Forsyth. 2005. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. 65:9982-9990. (Pubitemid 41541479)
16. Lun, X. Q., H. Zhou, T. Alain, B. Sun, L. Wang, J. W. Barrett, M. M. Stanford, G. McFadden, J. Bell, D. L. Senger, and P. A. Forsyth. 2007. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res. 67:8818-8827. (Pubitemid 47437458)
17. Ma, A., R. Koka, and P. Burkett. 2006. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu. Rev. Immunol. 24:657-679.
18. MacNeill, A. L., P. C. Turner, and R. W. Moyer. 2006. Mutation of the myxoma virus SERP2 P1-site to prevent proteinase inhibition causes apoptosis in cultured RK-13 cells and attenuates disease in rabbits, but mutation to alter specificity causes apoptosis without reducing virulence. Virology 356:12-22. (Pubitemid 44750025)
19. Magnani, E., L. Bartling, and S. Hake. 2006. From Gateway to MultiSite Gateway in one recombination event. BMC Mol. Biol. 7:46. (Pubitemid 44942822)
20. Mueller, K., O. Schweier, and H. Pircher. 2008. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy. Eur. J. Immunol. 38:2874-2885.
21. Munger, W., S. Q. DeJoy, R. Jeyaseelan, Sr., L. W. Torley, K. H. Grabstein, J. Eisenmann, R. Paxton, T. Cox, M. M. Wick, and S. S. Kerwar. 1995. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol. 165:289-293.
22. Oh, S., J. A. Berzofsky, D. S. Burke, T. A. Waldmann, and L. P. Perera. 2003. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. USA 100:3392-3397. (Pubitemid 36356594)
23. Perera, L. P., C. K. Goldman, and T. A. Waldmann. 2001. Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. Proc. Natl. Acad. Sci. USA 98:5146-5151. (Pubitemid 32397097)
24. Perera, L. P., T. A. Waldmann, J. D. Mosca, N. Baldwin, J. A. Berzofsky, and S. K. Oh. 2007. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J. Virol. 81:8774-8783.
25. Picker, L. J., E. F. Reed-Inderbitzin, S. I. Hagen, J. B. Edgar, S. G. Hansen, A. Legasse, S. Planer, M. Piatak, Jr., J. D. Lifson, V. C. Maino, M. K. Axthelm, and F. Villinger. 2006. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J. Clin. Investig. 116:1514-1524. (Pubitemid 43911006)
26. Stanford, M. M., J. W. Barrett, P. A. Gilbert, R. Bankert, and G. McFadden. 2007. Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits. J. Virol. 81:12704-12708. (Pubitemid 350085886)
27. Stanford, M. M., J. W. Barrett, S. H. Nazarian, S. Werden, and G. McFadden. 2007. Oncolytic virotherapy synergism with signaling inhibitors: rapamycin increases myxoma virus tropism for human tumor cells. J. Virol. 81:1251-1260. (Pubitemid 46167846)
28. Stanford, M. M., and G. McFadden. 2007. Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin. Biol. Ther. 7:1415-1425. (Pubitemid 47475657)
29. Stanford, M. M., M. Shaban, J. W. Barrett, S. J. Werden, P. A. Gilbert, J. Bondy-Denomy, L. Mackenzie, K. C. Graham, A. F. Chambers, and G. McFadden. 2008. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol. Ther. 16:52-59.
30. Stanford, M. M., S. J. Werden, and G. McFadden. 2007. Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet. Res. 38:299-318. (Pubitemid 46562409)
31. Sypula, J., F. Wang, Y. Ma, J. Bell, and G. McFadden. 2004. Myxoma virus tropism in human tumour cells. Gene Ther. Mol. Biol. 8:12.
32. Waldmann, T. A. 2006. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6:595-601. (Pubitemid 44134092)
33. Waldmann, T. A., S. Dubois, and Y. Tagaya. 2001. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14:105-110. (Pubitemid 32206513)
34. Wang, X., X. Zhang, Y. Kang, H. Jin, X. Du, G. Zhao, Y. Yu, J. Li, B. Su, C. Huang, and B. Wang. 2008. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus. Vaccine 26:5135-5144.
35. Winnard, P. T., Jr., J. B. Kluth, and V. Raman. 2006. Noninvasive optical tracking of red fluorescent protein-expressing cancer cells in a model of metastatic breast cancer. Neoplasia 8:796-806. (Pubitemid 44564835)
36. Xiong, C., P. M. Hixson, L. H. Mendoza, and C. W. Smith. 2005. Cloning and expression of rabbit interleukin-15. Vet. Immunol. Immunopathol. 107:131-141. (Pubitemid 40848511)
37. Yajima, T., H. Nishimura, W. Wajjwalku, M. Harada, H. Kuwano, and Y. Yoshikai. 2002. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int. J. Cancer 99:573-578.
38. + T cells in vivo by IL-15. Immunity 8:591-599.